Targeted therapies are rapidly advancing for non-small cell lung cancer making conservation of tissue and choice of testing method key to obtaining the best treatment pathway for patients. This will cover current molecular testing guidelines, recent advances in gene targets and best practice for clinicians and pathology laboratories undertaking molecular testing in NSCLC.